Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia

Robert Q Le, Donna Przepiorka, Haiyan Chen, Yuan Li Shen, E. Dianne Pulte, Kelly J Norsworthy, Marc R. Theoret, R. Angelo De Claro

Blood blood.2023023313.

https://doi.org/10.1182/blood.2023023313

Published: 2024

Includes: Supplemental data

Journal Articles

Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data

Vishal Bhatnagar, Bindu Kanapuru, Laura Fernandes, Ting-Yu Chen, Mallorie H. Fiero, Erica Horodniceanu, Nicole Gormley, Catherine Lerro, Fatima Rizvi, Yuan-Li Shen, Felice Yang, Anna Barcellos, Andrew J. Belli, Eric Hansen, Ching-Kun Wang, Donna Rivera, Paul Kluetz

Blood (2022) 140 (Supplement 1): 7156–7157.

https://doi.org/10.1182/blood-2022-166842

Published: 2022

Journal Articles

FDA Analysis of Survival Outcomes in Older Adults with Relapsed-Refractory Multiple Myeloma (RRMM) Treated with Novel Drug Regimens

Bindu Kanapuru, MD, Susan Jin, Kunthel By, Theresa Carioti, Yuan-Li Shen, PhD, Rajeshwari Sridhara, PhD, Nicole J Gormley, MD, Ann T. Farrell, MD, Richard Pazdur, MD

Blood (2019) 134 (Supplement_1): 3194.

https://doi.org/10.1182/blood-2019-127141

Published: 2019

Journal Articles

Response Rate, Event-Free Survival (EFS), and Overall Survival (OS) in Newly-Diagnosed Acute Myeloid Leukemia (AML): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

Kelly J. Norsworthy, MD, Xin Gao, PhD, Chia-Wen Ko, PhD, Jiaxi Zhou, MS, Yutao Gong, PhD, Yuan Li Shen, PhD, Rajeshwari Sridhara, PhD, Albert B. Deisseroth, MD PhD, Ann T. Farrell, MD, Richard Pazdur, MD, Gideon Blumenthal, MD

Blood (2018) 132 (Supplement 1): 2670.

https://doi.org/10.1182/blood-2018-99-119678

Published: 2018

Journal Articles

FDA Analysis of Outcomes in Older Adults with Relapsed or Refractory Multiple Myeloma

Bindu Kanapuru, MD, Susan Jin, Kunthel By, Yuan Li Shen, PhD, Theresa Carioti, Nicole Gormley, MD, Ann T. Farrell, MD, Richard Pazdur, MD

Blood (2018) 132 (Supplement 1): 3287.

https://doi.org/10.1182/blood-2018-99-118597

Published: 2018

NARROW

Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia

Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data

FDA Analysis of Survival Outcomes in Older Adults with Relapsed-Refractory Multiple Myeloma (RRMM) Treated with Novel Drug Regimens

Response Rate, Event-Free Survival (EFS), and Overall Survival (OS) in Newly-Diagnosed Acute Myeloid Leukemia (AML): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

FDA Analysis of Outcomes in Older Adults with Relapsed or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia

Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data

FDA Analysis of Survival Outcomes in Older Adults with Relapsed-Refractory Multiple Myeloma (RRMM) Treated with Novel Drug Regimens

Response Rate, Event-Free Survival (EFS), and Overall Survival (OS) in Newly-Diagnosed Acute Myeloid Leukemia (AML): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

FDA Analysis of Outcomes in Older Adults with Relapsed or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only